TCM
TARS icon

TCG Crossover Management’s Tarsus Pharmaceuticals TARS Stock Holding History

TCG Crossover Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-231,820
Closed -$7.62M – 41
2024
Q3 		$7.62M Sell
231,820
-324,497
-58% -$9.12M 0.65% 28
2024
Q2 		$15.1M Sell
556,317
-237,512
-30% -$7.99M 1.58% 21
2024
Q1 		$28.9M Sell
793,829
-349,028
-31% -$10.3M 2.28% 20
2023
Q4 		$23.1M Hold
1,142,857
– – 2.57% 17
2023
Q3 		$20.3M Buy
+1,142,857
New +$20.2M 2.99% 16

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

TCG Crossover Management's TARS Position: Q4 2024 in Review

TCG Crossover Management sold out of Tarsus Pharmaceuticals (TARS) in Q4 2024, closing a stake of 231,820 shares — an estimated $7.62M sold.

TCG Crossover Management first reported a position in TARS in Q3 2023 and held it in 5 quarters. The position peaked at $28.9M in Q1 2024. 195 funds tracked by Wall St. Rank hold TARS as of Q4 2024.

  • TCG Crossover Management reported no remaining Tarsus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • TCG Crossover Management sold 231,820 Tarsus Pharmaceuticals shares in Q4 2024, an estimated $7.62M.
  • TCG Crossover Management first reported a position in Tarsus Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • TCG Crossover Management's Tarsus Pharmaceuticals position peaked at $28.9M in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2024.

Based on TCG Crossover Management's 13F filing for Q4 2024, filed 14 Feb 2025.